Ann: Positive preclinical data for deoxymabs in vasculitis, page-55

that’s to bring it to approval/market (15 years ) and that’s for a chemical drug - not a monoclonal antibody that should take less ( 7 to 8 years maximum ) being a biological ( not a chemical entity ) and - arguably much less since COVID:


That’s IND , Lastly, the main patent will expire in 2031, at this pace - with phase 1 hopefully starting in 2025, would then be enough exclusivity for a BP to get an interest in it considering that phase2 and phase3 trials would push its eventual commercialisation to - optimistically- to 2028 ???